Trial reportEuropean heart journal2021
Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease.
Trial report in European heart journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SYNTAX Study: SYNergy Between PCI With TAXUS and Cardiac Surgery
Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Comparing outcomes between coronary artery bypass grafting and percutaneous coronary intervention in octogenarians with left main or multivessel disease.Scientific reports · 2023Pooled it
- Impact of repeat revascularization within 5 years on 10-year mortality after percutaneous or surgical revascularization.Clinical research in cardiology : official journal of the German Cardiac Society · 2023Trial
- Drug-Coated Balloon Percutaneous Coronary Intervention in Diabetic and Non-Diabetic Patients: A Large All-Comers Cohort of Mid-Term Outcomes and Predictors of Adverse Events.Journal of clinical medicine · 2026Article
- Implementation of revascularization guidelines for diabetics with chronic coronary syndromes in clinical practice: findings from the German ALKK registry.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Association between impaired peripheral thyroid hormone sensitivity and coronary heart disease in type 2 diabetes: the potential mediating role of albumin.Frontiers in endocrinology · 2026Article
- Impact of Periprocedural Risk Predictors on Long-Term Outcomes in Patients with Diabetes Undergoing Coronary Artery Bypass Grafting.Medicina (Kaunas, Lithuania) · 2025Article
- Evolution of Coronary Stents: From Birth to Future Trends.Journal of clinical medicine · 2025Review
- Ten-Year Outcomes of Patients with Left Main Coronary Artery Disease and Diabetes Mellitus Treated with Percutaneous Coronary Intervention.Journal of clinical medicine · 2025Article
- Real-world study to compare functional SYNTAX score versus anatomical SYNTAX score in influencing the treatment strategy for multivessel disease patients.Scientific reports · 2025Article
- Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention for Left Main Coronary Artery Disease-Long-Term Outcomes.Journal of clinical medicine · 2025Article
- Coronary imaging characteristics and risk factors in patients with type 2 diabetes mellitus with coronary heart disease complication.World journal of diabetes · 2025Article
- Myocardial Revascularization in Patients with Diabetes and Heart Failure-A Narrative Review.International journal of molecular sciences · 2025Review
- Assessing hemodynamic changes before and after pump in CABG surgery and its factors.ARYA atherosclerosis · 2025Article
- Diabetes and calcific aortic valve disease: controversy of clinical outcomes in diabetes after aortic valve replacement.Frontiers in endocrinology · 2025Review
- An Endothelial Cell Is Not Simply an Endothelial Cell.Stem cells and development · 2024Review
- Examination of Postoperative Changes in Lipid Profile and Glycemic Markers After Coronary Artery Bypass Graft, Percutaneous Intervention Vs Aortic Valve Replacement Demonstrated a Shift in Risk Factors for Coronary Artery Disease.Journal of multidisciplinary healthcare · 2024Article
- 10 Years of SYNTAX: Closing an Era of Clinical Research After Identifying New Outcome Determinants.JACC. Asia · 2023Review
- Impact of periprocedural major adverse events on 10-year mortality after revascularisation.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2023Article
- A review of recent advances in the diagnosis of cardiac amyloidosis, treatment of its cardiac complications, and disease-modifying therapies.F1000Research · 2023Review
- Modifiers of the Risk of Diabetes for Long-Term Outcomes After Coronary Revascularization: CREDO-Kyoto PCI/CABG Registry.JACC. Asia · 2022Article
Corrections and comments
- Commented on by
Authors and funding
23 authors at 12 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aim of this article was to compare rates of all-cause death at 10 years following coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) in patients with or without diabetes. METHODS AND
resultsThe SYNTAXES study evaluated up to 10-year survival of 1800 patients with three-vessel disease (3VD) and/or left main coronary artery disease (LMCAD) randomized to receive either PCI or CABG in the SYNTAX trial. Ten-year all-cause death according to diabetic status and revascularization strategy was examined. In diabetics (n = 452), the risk of mortality was numerically higher with PCI compared with CABG at 5 years [19.6% vs. 13.3%, hazard ratio (HR): 1.53, 95% confidence interval (CI): 0.96, 2.43, P = 0.075], with the opposite seen between 5 and 10 years (PCI vs. CABG: 20.8% vs. 24.4%, HR: 0.82, 95% CI: 0.52, 1.27, P = 0.366). Irrespective of diabetic status, there was no significant difference in all-cause death at 10 years between patients receiving PCI or CABG, the absolute treatment difference was 1.9% in diabetics (PCI vs. CABG: 36.4% vs. 34.5%, difference: 1.9%, 95% CI: -7.6%, 11.1%, P = 0.551). Among insulin-treated patients (n = 182), all-cause death at 10 years was numerically higher with PCI (47.9% vs. 39.6%, difference: 8.2%, 95% CI: -6.5%, 22.5%, P = 0.227).
conclusionsThe treatment effects of PCI vs. CABG on all-cause death at 10 years in patients with 3VD and/or LMCAD were similar irrespective of the presence of diabetes. There may, however, be a survival benefit with CABG in patients with insulin-treated diabetes. The association between revascularization strategy and very long-term ischaemic and safety outcomes for patients with diabetes needs further investigation in dedicated trials.
trial registrationSYNTAX: ClinicalTrials.gov reference: NCT00114972 and SYNTAX Extended Survival: ClinicalTrials.gov reference: NCT03417050.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.